HIV infections Trials in Los Angeles, United States
Conditions / HIV infections / Los Angeles, United States
HIV infections has been the subject of sustained clinical investigation across multiple research sites.
670 total trials for this combination
Showing top 10 of 670 trials
Trials
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT01815736 | Study to Evaluate Switching From a TDF-Containing Combination Regimen to a TAF-Containing Fixed Dose Combination (FDC) in Virologically-Suppressed, HIV-1 Positive Participants | COMPLETED | PHASE3 |
| NCT01095796 | Study to Evaluate the Safety and Efficacy of Stribild Versus Atripla in Human Immunodeficiency Virus, Type 1 (HIV-1) Infected, Antiretroviral Treatment-Naive Adults | COMPLETED | PHASE3 |
| NCT01780506 | Study to Evaluate the Safety and Efficacy of E/C/F/TAF (Genvoya®) Versus E/C/F/TDF (Stribild®) in HIV-1 Positive, Antiretroviral Treatment-Naive Adults | COMPLETED | PHASE3 |
| NCT00245739 | TMC114-C226: An Early Access Program to Evaluate the Long-term Safety and Tolerability of TMC114 Combined With a Low Dose of Ritonavir (TMC114/r) With Other Antiretrovirals, for HIV-1 Infected Patients Who Have Failed Multiple Antiretroviral Regimens. | APPROVED_FOR_MARKETING | — |
| NCT00146328 | Rollover Trial Safety and Tolerability of Combination Tipranavir and Ritonavir Use in HIV 1 Infected Subjects | COMPLETED | PHASE2/PHASE3 |
| NCT01108510 | Safety and Efficacy of COBI-boosted Atazanavir Versus Ritonavir-boosted Atazanavir Each Administered With Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Infected, Antiretroviral Treatment-Naive Adults | COMPLETED | PHASE3 |
| NCT01106586 | Study to Evaluate the Safety and Efficacy of Stribild Versus Ritonavir-Boosted Atazanavir Plus Truvada in Human Immunodeficiency Virus, Type 1 (HIV-1) Infected, Antiretroviral Treatment-Naive Adults | COMPLETED | PHASE3 |
| NCT01797445 | Study to Evaluate the Safety and Efficacy of E/C/F/TAF Versus E/C/F/TDF in HIV-1 Positive, Antiretroviral Treatment-Naive Adults | COMPLETED | PHASE3 |
| NCT00426660 | Expanded Access Program for Maraviroc At Multiple Centers | COMPLETED | PHASE3 |
| NCT01231516 | A Study of GSK1349572 Versus Raltegravir (RAL) With Investigator Selected Background Regimen in Antiretroviral-Experienced, Integrase Inhibitor-Naive Adults | COMPLETED | PHASE3 |